Abstract: Lazertinib (YH25448) is a highly selective, third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for the treatment of advanced non-small cell lung cancer (NSCLC). Designed to overcome the limitations of earlier generation TKIs, lazertinib demonstrates potent activity against classical EGFR sensitizing mutations (Ex19del, L858R) as well as the T790M resistance mutation, while sparing wild-type EGFR. Recent clinical advancements have highlighted its exceptional central nervous system (CNS) penetrance and its synergistic efficacy when combined with the bispecific antibody amivantamab. This combination has shown remarkable progression-free survival benefits in both treatment-naïve and refractory NSCLC patients, including those with atypical EGFR mutations. However, challenges such as the emergence of the C797S tertiary mutation and combination-related toxicities necessitate ongoing research. This review synthesizes the pharmacological profile, molecular mechanisms, structure-activity relationships, current limitations, and future perspectives of lazertinib in the management of EGFR-mutated NSCLC.
1. Introduction
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have revolutionized the therapeutic landscape for patients with advanced NSCLC harboring EGFR-activating mutations, such as exon 19 deletions (Ex19del) and exon 21 L858R point mutations [3] [16]. Despite the initial success of first- and second-generation TKIs (e.g., gefitinib, erlotinib, afatinib), acquired resistance inevitably develops, most commonly driven by the EGFR T790M "gatekeeper" mutation [3] [12]. This clinical challenge spurred the development of third-generation TKIs, notably osimertinib and lazertinib, which selectively target both sensitizing mutations and the T790M variant [4] [12]. Lazertinib (YH25448, Lazcluze) was deliberately engineered to improve upon the medicinal chemistry profile of osimertinib, offering superior mutant selectivity, enhanced blood-brain barrier penetration, and a favorable safety profile as a monotherapy [3] [4]. Recently, lazertinib has gained significant attention for its role in combination regimens, particularly with amivantamab, to treat both classical and atypical EGFR-mutated NSCLC, as well as refractory cases [1] [7].
2. Pharmacological Activity
Lazertinib exhibits robust pharmacological activity in both monotherapy and combination settings. In the phase 3 LASER301 trial, lazertinib monotherapy demonstrated a significant progression-free survival (PFS) benefit compared to gefitinib (20.6 vs. 9.7 months) in first-line treatment of EGFR-mutated advanced NSCLC [2]. Notably, lazertinib has shown the greatest PFS benefit among TKIs in patients with the L858R mutation [16]. Furthermore, lazertinib possesses excellent blood-brain barrier permeability (unbound brain-to-plasma partition coefficient [Kpuu] of 0.29), translating to potent intracranial activity with an intracranial objective response rate (ORR) reaching up to 94.4% in patients with brain metastases [2] [3].
In the refractory and atypical mutation settings, the combination of lazertinib with amivantamab (a bispecific EGFR/c-MET antibody) has proven highly effective. The CHRYSALIS-2 trial explored this combination in heavily pretreated patients and those with rarer, atypical EGFR mutations (e.g., exon 20 insertions, S768I, L861Q, G719X), demonstrating durable antitumor activity [4] [7]. The landmark phase 3 MARIPOSA trial established the superiority of the lazertinib and amivantamab combination over osimertinib monotherapy in previously untreated patients, extending median PFS to 23.7 months compared to 16.6 months for osimertinib [6] [10].
3. Molecular Mechanism of Action
Lazertinib is an irreversible, mutant-selective EGFR inhibitor. It exerts its primary mechanism of action by forming a covalent bond with the Cys797 (C797) residue located within the ATP-binding pocket of the mutant EGFR kinase domain [4] [12]. By doing so, it potently inhibits EGFR downstream signaling pathways, including the phosphorylation of EGFR, AKT, and ERK, ultimately inducing apoptosis in EGFR-mutant lung cancer cells [3].
When used in combination with amivantamab, the therapeutic strategy employs a synergistic "one-two punch." While lazertinib targets the intracellular catalytic domain of EGFR, amivantamab binds to the extracellular domains of both EGFR and MET [1] [4]. This dual blockade not only bypasses intracellular resistance mutations but also actively degrades the receptors and induces immune-mediated cell death (such as antibody-dependent cellular cytotoxicity and trogocytosis) [6] [14]. This comprehensive mechanism proactively suppresses the emergence of common resistance pathways, such as MET amplification [9].
4. Structure-Activity Relationship (SAR)
The structural design of lazertinib represents a deliberate evolution from osimertinib to enhance mutant selectivity and reduce off-target toxicities. Lazertinib differs from osimertinib by replacing the indole ring on the pyrimidine scaffold with a 4-phenyl-3-dimethylaminomethyl-1-pyrazole group, and by substituting the dimethylaminoethyl-N-methyl chain at the 2-position of the phenyl ring with a morpholine group [2].
X-ray cocrystal structures reveal that the substituted pyrazole moiety is critical for lazertinib's selectivity. The hydrophobic phenyl ring engages in productive van der Waals interactions with the T790M gatekeeper mutation, while the hydrophilic methyleneamine group forms an intramolecular hydrogen bond with the acrylamide warhead or interacts with the D855 residue [4]. In wild-type (WT) EGFR, the local polarity of the binding pocket opposes the hydrophobic phenyl ring, which weakens lazertinib's reversible binding to WT EGFR compared to osimertinib. This structural nuance provides a basis for lazertinib's superior T790M-selectivity and its diminished inhibition of WT EGFR and closely related kinases like HER2, thereby widening its therapeutic window [4].
5. Current Limitations
Despite its efficacy, lazertinib faces significant clinical limitations, primarily related to acquired resistance and combination-therapy toxicity. Like other third-generation TKIs, lazertinib is highly vulnerable to the tertiary EGFR C797S mutation. The substitution of cysteine with serine at position 797 eliminates the nucleophilic target required for lazertinib's acrylamide warhead to form its potency-enabling covalent bond, rendering the drug ineffective [4] [12]. Other identified "off-target" resistance mechanisms include MET amplification, PIK3CA alterations, and TP53 mutations [3] [9].
Furthermore, while lazertinib monotherapy is generally well-tolerated, its combination with amivantamab introduces substantial toxicity. In the MARIPOSA trial, 75% of patients receiving the combination experienced grade 3 or higher treatment-related adverse events (TRAEs), compared to 43% in the osimertinib arm [5] [9]. Common severe toxicities include dermatologic events (paronychia, rash), infusion-related reactions, hypoalbuminemia, and an increased risk of venous thromboembolic events (VTEs) [3] [9]. These toxicities necessitate careful patient selection and well-structured shared decision-making in clinical practice [11].
6. Future Perspectives
The future of lazertinib in NSCLC management lies in optimizing its combination regimens and overcoming acquired resistance. To address the high rate of infusion-related reactions and improve patient convenience, ongoing phase 3 trials (e.g., PALOMA-3) are evaluating subcutaneous formulations of amivantamab in combination with lazertinib [4] [11]. Additionally, trials like MARIPOSA-2 are exploring the integration of lazertinib and amivantamab with platinum-based chemotherapy for patients who have progressed on prior osimertinib therapy [4] [14].
To combat the inevitable emergence of the C797S mutation, drug discovery efforts are pivoting toward advanced reversible ATP-competitive inhibitors, allosteric degraders, and novel antibody-drug conjugates (ADCs) [4] [14]. The paradigm of NSCLC treatment is shifting away from sequential monotherapies toward upfront, multi-targeted combination strategies designed to anticipate and suppress diverse resistance mechanisms simultaneously [4].
